4974.T Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 Mai 2024 @ 08:15):

Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally...

Stats
Tagesvolumen	123 000
Durchschnittsvolumen	363 617
Marktkapitalisierung	121.62B
EPS	¥0 ( 2024-02-14 )
Nächstes Ertragsdatum	( ¥14.90 ) 2024-05-09
Last Dividend	¥42.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	77.51
ATR14	¥0.594 (0.06%)

Volumen Korrelation

Lang: -0.07 (neutral)

Kurz: 0.33 (neutral)

Signal:(55.628) Neutral

Takara Bio Inc. Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Takara Bio Inc. Korrelation - Währung/Rohstoff

0.29
( neutral )

0.33
( neutral )

-0.15
( neutral )

0.18
( neutral )

0.36
( neutral )

0.19
( neutral )

Takara Bio Inc. Finanzdaten

Annual	2022
Umsatz:	¥78.14B
Bruttogewinn:	¥44.77B (57.29 %)
EPS:	¥132.97

FY	2022
Umsatz:	¥78.14B
Bruttogewinn:	¥44.77B (57.29 %)
EPS:	¥132.97

FY	2022
Umsatz:	¥67.70B
Bruttogewinn:	¥49.21B (72.69 %)
EPS:	¥164.84

FY	2021
Umsatz:	¥46.09B
Bruttogewinn:	¥31.87B (69.16 %)
EPS:	¥79.29

Financial Reports:

No articles found.

Takara Bio Inc. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥0 (N/A)	¥0 (N/A)	¥42.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Takara Bio Inc. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 8.16 - good (81.59%) | Divividend Growth Potential Score: 6.07 - Stable (21.50%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥1.000	2012-03-28
Last Dividend	¥42.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	13	--
Total Paid Out	¥114.10	--
Avg. Dividend % Per Year	0.00%	--
Score	2.77	--
Div. Sustainability Score	8.16
Div.Growth Potential Score	6.07
Div. Directional Score	7.12	--

Next Divdend (Est)
(2024-12-31)

¥0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

2.77

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8214.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7595.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6788.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
6135.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
4837.T	Ex Dividend Junior	2024-03-28	Sporadic	0.00%
4045.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
3271.T	Ex Dividend Junior	2024-06-27	Sporadic	0.00%
2294.T	Ex Dividend Junior	2024-04-26	Annually	0.00%
9535.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7999.T	Ex Dividend Junior	2023-09-28	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0330	1.500	9.34	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0128	1.200	9.57	10.00	[0 - 0.3]
returnOnEquityTTM	0.0141	1.500	-0.954	-1.431	[0.1 - 1]
payoutRatioTTM	3.21	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	7.45	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	5.46	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	4.25	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	61.42	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	200.29	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	81.73	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.553	1.000	4.11	4.11	[0.2 - 0.8]
operatingProfitMarginTTM	0.0309	1.000	-1.382	-1.382	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.387	0.800	-0.751	-0.601	[0.5 - 2]
Total Score				8.16

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	77.42	1.000	2.28	0	[1 - 100]
returnOnEquityTTM	0.0141	2.50	-0.613	-1.431	[0.1 - 1.5]
freeCashFlowPerShareTTM	81.73	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	1.683	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	200.29	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	3.21	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	53.61	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.506	1.000	10.00	0	[0.1 - 0.5]
Total Score				6.07

Takara Bio Inc.

Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally. The company operates through Bioindustry and Gene Therapy segments. It develops research reagents and scientific instruments; and provides contract development and manufacturing organization (CDMO) services for academic and corporate life sciences research and development. The company's CDMO services include contract service for developing regenerative medicine products; related services, such as quality and safety testing, and cell banking; and contract services for supporting genetic analysis and testing comprising human genome sequence analysis, analysis of cancerrelated genes, and intestinal flora analysis, as well as support services for genetic engineering research, such as genome editing using the latest technologies and equipment. It also engages in the development and commercialization of various gene therapies, including oncolytic virus utilizing Canerpaturev, which is an attenuated strain of the herpes simplex virus type 1 that exhibits antitumor activity upon local injection into a tumor due to tumor lysis; siTCR gene therapy, which is in Phase I/II clinical trials for the treatment of synovial sarcoma; and CD19 chimeric antigen receptors that is in Phase I/II clinical trial for the treatment of adult acute lymphoblastic leukemia. Additionally, the company offers RetroNectin for gene therapy. The company was founded in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.

Echtzeitaktualisierungen für Takara Bio Inc. [4974.T]

Upcoming Earnings Alert

Takara Bio Inc. Dividend Information - Ex Dividend Junior

Dividend Commentary

Top 10 dividend Companies for JPX

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)